Related Experiment Video
Updated: Aug 9, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
[WT1 gene expression in myelodysplastic syndrome and its clinical implication]
Jian Huang1, Jie Jin, Wei-lai Xu
1The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Summary
WT1 gene expression is elevated in myelodysplastic syndromes (MDS) compared to healthy individuals. This finding suggests WT1 can aid in MDS risk assessment and monitoring disease progression.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Context:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Aberrant gene expression plays a critical role in MDS pathogenesis.
- Understanding molecular markers is crucial for MDS diagnosis and management.
Purpose:
- To investigate the expression levels of the WT1 gene in patients diagnosed with myelodysplastic syndromes (MDS).
- To explore the potential clinical implications of WT1 gene expression in MDS, including its association with disease subtypes and progression.
- To evaluate WT1 as a potential biomarker for risk assessment and monitoring therapeutic efficacy in MDS.
Summary:
- WT1 mRNA expression was quantified using reverse transcriptase polymerase chain reaction (RT-PCR) in 53 MDS patients and 10 healthy controls.
- Significantly higher WT1 expression rates and levels were observed in MDS patients compared to healthy subjects.
- Expression levels increased progressively across MDS subtypes, from MDS-RA/RAS to MDS-RAEB/RAEB-t, indicating a correlation with disease severity.
Impact:
- WT1 gene expression is a potential indicator associated with MDS development.
- WT1 may serve as a valuable biomarker for risk stratification in MDS patients.
- Monitoring WT1 expression could facilitate disease progression tracking and assessment of treatment response in MDS.
